Actio Biosciences to Be Acquired by Jazz Pharmaceuticals for Up to $1.32 Billion

Cooley advised Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel small molecule precision medicines, on its agreement to be acquired by Jazz Pharmaceuticals for $820 million upfront payment and up to $500 million in potential approval and sales milestones. As part of the transaction, and concurrently with closing, Actio Biosciences will spin out a new privately-held entity with certain management, employees and assets (not including ABS-1230 which remains with Actio Biosciences and is being acquired by Jazz).

The transaction was announced publicly in the following press release, which can be viewed here.

Bill Roegge, Jamie Leigh, Marc Recht and Carlos Ramirez led the Cooley team advising Actio Biosciences.

Christophe Beauduin, Mark Windfeld-Hanson, David Burns, Ariane Andrade, Sarah O’Gorman, Patrick Reed, Matt Choy, Navya Dasari, David Dalton, Michael Egan, Todd Gluth, Daniel Knauss, Lauren Leonard, Mika Mayer, John Paul Oleksiuk, Sanjay Reddy, Chad Shear, Rubin Waranch, and Joanna Zhang provided invaluable support.

Cooley previously advised Actio Biosciences on its $55 million Series A (2023) and $66 million Series B (2025).

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.